TWiV 1072: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses the annual economic burden of respiratory syncytial virus in adults in the US, recombinant or standard-dose influenza vaccine in adults under 65 years of age, maternal vaccine effectiveness against influenza-associated hospitalizations and emergency department visits in iInfants, influenza positive tests reported to CDC by US clinical laboratories, update on COVID-19, risk of severe maternal morbidity associated with SARS-CoV-2 infection during pregnancy, COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens, optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation, long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study, and risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study. Subscribe (free): Apple Podcasts , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode RSV economic burden , US (J Inf Dis) Recombinant or standard dose influenza vaccine (NEJM) Maternal vaccine effectiveness against influenza in Infants (JAMA Ped) Weekly influenza surveillance report (MMWR) COVID data tracker ( hospital admissions , national trend ) Risk of severe maternal morbidity associated with SARS-CoV-2 infection (J Inf Dis) COVID-19 rapid antigen tests with nasal and throat swab specimens (JAMA Net Open) Optimal timing of nirmatrelvir/ritonavir (Nat Comm) Long-term outcomes following hospital admission for COVID-19 vs influenza (Lancet) Contribute to our MicrobeTV fundraiser at PWB Letters read on TWiV 1072 Dr. Griffin's COVID treatment summary ( pdf ) Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]